MedWatch

Zealand Pharma's restructuring plan has led to dismissals in Denmark

Last week’s announcement that Zealand Pharma was planning to scale down its operations in the US by 90 percent has had a wider impact than first assumed – CEO Adam Steensberg now tells MedWatch that Danish staffing has also been reduced.

Adam Steensberg, CEO of Zealand Pharma | Photo: Zealand Pharma

More than just Zealand Pharma’s employees in the US are bearing the brunt of the company’s streamlining plans. Danish staffing has also suffered a blow, says the newly appointed CEO, Adam Steensberg, to MedWatch.

Last week, Zealand Pharma announced that a 90-percent reduction of its workforce in the US will take place in Q3 of this year in connection with a larger restructuring plan. At the same time, the company also mentioned that ”additional cost reductions” would be implemented in Denmark.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs